|BioTime and Processa Announce Their Intention to Enter into a HyStem® Sublicense for Drug Delivery|
“We are excited to form this new relationship with Processa. Dr.
“The Processa team and I are excited about accessing the HyStem
technology platform as a way to address the numerous challenges that
exist within drug delivery. This technology has the potential to be
beneficial for many drugs. We are keen to make progress on the
development of the HyStem platform for drug delivery,” said Dr.
HyStem® is BioTime’s cell and drug delivery platform. HyStem®
technology includes a family of unique, biocompatible hydrogels designed
to effectively deliver cells or bioactive compositions for therapeutic
benefit. HyStem® was designed to enable the effective
transfer, engraftment and metabolic support for cells and is the basis
of BioTime’s Renevia® program. The flexible chemistry of the
HyStem® also allows for hydrogel optimization in the delivery
of drugs and therapeutics.
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter, LinkedIn,
To receive ongoing
Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for